eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase II study of sorafenib (NSC-724772) and erlotinib (NSC-718781) in patients with advanced gallbladder carcinoma or cholangiocarcinoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Erlotinib hydrochloride
  3. Intervention
    Sorafenib tosylate
  4. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  5. Resource Description
    RATIONALE: Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.
  6. Contact
    Berenberg, Jeffrey
  7. PI
    Berenberg, Jeffrey
  8. Topic
    gallbladder cancer
  9. Study Population
    Males and females from age 18 Years and older are eligible.
  10. Funded by
  11. Phase
    Phase 2 clinical trial
  12. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016